{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:40:04Z","timestamp":1791373204592,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":116,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["nmd-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.nmd.2020.05.002","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T02:36:44Z","timestamp":1589855804000},"page":"492-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"30","author":[{"given":"Kathryn R.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda Z.","family":"Abdel-Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean K.","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kostera-Pruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Karachunski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico S.","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Statland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesia B.","family":"Sadosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek S.","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Sherlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Binks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Charnas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Marraffino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2020.05.002_bib0001","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0002","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1056\/NEJMp048124","article-title":"Powerful genes\u2013myostatin regulation of human muscle mass","volume":"350","author":"McNally","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2020.05.002_bib0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2020.05.002_bib0004","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","article-title":"Functional improvement of dystrophic muscle by myostatin blockade","volume":"420","author":"Bogdanovich","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2020.05.002_bib0005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1096\/fj.04-2796com","article-title":"Myostatin propeptide-mediated amelioration of dystrophic pathophysiology","volume":"19","author":"Bogdanovich","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.nmd.2020.05.002_bib0006","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13395-018-0180-z","article-title":"Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone","volume":"8","author":"Iskenderian","year":"2018","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.nmd.2020.05.002_bib0007","doi-asserted-by":"crossref","first-page":"19371","DOI":"10.1074\/jbc.M802585200","article-title":"Myostatin directly regulates skeletal muscle fibrosis","volume":"283","author":"Li","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nmd.2020.05.002_bib0008","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/hum.2007.159","article-title":"Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice","volume":"19","author":"Qiao","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nmd.2020.05.002_bib0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13395-017-0141-y","volume":"7","author":"St Andre","year":"2017","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.nmd.2020.05.002_bib0010","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1073\/pnas.0408729102","article-title":"Muscle regeneration in the prolonged absence of myostatin","volume":"102","author":"Wagner","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmd.2020.05.002_bib0011","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ana.10385","article-title":"Loss of myostatin attenuates severity of muscular dystrophy in mdx mice","volume":"52","author":"Wagner","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17987\/jcsm-cr.v2i1.37","article-title":"Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy","volume":"2","author":"Saitoh","year":"2017","journal-title":"JCSM Clinical Reports"},{"key":"10.1016\/j.nmd.2020.05.002_bib0013","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2004-10-3982","article-title":"MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients","volume":"106","author":"Wood","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.nmd.2020.05.002_bib0014","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.05.002_bib0015","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.nmd.2010.06.014","article-title":"North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy","volume":"20","author":"Mazzone","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.05.002_bib0016","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nmd.2009.06.368","article-title":"Reliability of the North Star Ambulatory Assessment in a multicentric setting","volume":"19","author":"Mazzone","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.05.002_bib0017","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1164\/ajrccm.164.12.2103052","article-title":"Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy","volume":"164","author":"Phillips","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2020.05.002_bib0018","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/ptj\/65.9.1339","article-title":"Reliability of goniometric measurements in patients with Duchenne muscular dystrophy","volume":"65","author":"Pandya","year":"1985","journal-title":"Phys Ther"},{"key":"10.1016\/j.nmd.2020.05.002_bib0019","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/dmcn.12213","article-title":"Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy","volume":"55","author":"Mayhew","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.nmd.2013.11.014","article-title":"Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy","volume":"24","author":"Pane","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.05.002_bib0021","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/mus.21808","article-title":"The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations","volume":"42","author":"McDonald","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.05.002_bib0022","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmd.2020.05.002_bib0023","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2020.05.002_bib0024","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.23807","article-title":"The cooperative international neuromuscular research group Duchenne natural history study\u2013a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.05.002_bib0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/ana.24599","article-title":"Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort","volume":"79","author":"Willcocks","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0026","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00415-016-8311-0","article-title":"Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy","volume":"264","author":"Willcocks","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0027","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.05.002_bib0028","first-page":"561","article-title":"The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change","volume":"18","author":"Daltroy","year":"1998","journal-title":"Pediatric Outcomes Instrument Development Group. Pediatric Orthopaedic Society of North America. J Pediatr Orthop"},{"key":"10.1016\/j.nmd.2020.05.002_bib0029","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.nmd.2020.05.002_bib0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/acn3.319","article-title":"Longitudinal MRI quantification of muscle degeneration in Duchenne muscular dystrophy","volume":"3","author":"Godi","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0031","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41467-017-01486-4","article-title":"Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches","volume":"8","author":"Mariot","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmd.2020.05.002_bib0032","article-title":"Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle","author":"Hammers","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.nmd.2020.05.002_bib0033","unstructured":"St. Andre M, Berryman ER, Zakur DE, Liu C-N, Goldstein R, Peng Q, et al. A murine anti-myostatin antibody induces skeletal muscle hypertrophy in B10-mdx mice treated daily with a corticosteroid, https:\/\/com-pharm-myology.sites.medinfo.ufl.edu\/files\/2018\/06\/2018-New-Directions-Conference-Program-Book_Website.pdf; 2018[accessed [Epub ahead of print]."},{"key":"10.1016\/j.nmd.2020.05.002_bib0034","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial","volume":"385","author":"Buyse","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2020.05.002_bib0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2020.05.002_bib0036","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2020.05.002_bib0037","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1991.00530160047012","article-title":"Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group","volume":"48","author":"Griggs","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0038","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2020.05.002_bib0039","first-page":"38","article-title":"Prednisolone in Duchenne muscular dystrophy","volume":"27","author":"Rahman","year":"2001","journal-title":"Bangladesh Med Res Counc Bull"},{"key":"10.1016\/j.nmd.2020.05.002_bib0040","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4155\/cli.11.113","article-title":"Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings","volume":"1","author":"Bushby","year":"2011","journal-title":"Clin Investig (Lond)"},{"key":"10.1016\/j.nmd.2020.05.002_bib0041","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2020.05.002_bib0042","article-title":"The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year","volume":"5","author":"Henricson","year":"2013","journal-title":"PLoS Curr"},{"key":"10.1016\/j.nmd.2020.05.002_bib0043","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/0883073810371509","article-title":"Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy","volume":"25","author":"McDonald","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0044","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4161\/mabs.2.5.12833","article-title":"Properties of a general PK\/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets","volume":"2","author":"Davda","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.nmd.2020.05.002_bib0045","article-title":"Application of quantitative pharmacology approaches in bridging pharmacokinetics and pharmacodynamics of domagrozumab from adult healthy subjects to pediatric patients with Duchenne muscular disease","author":"Bhattacharya","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0046","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cpdd.386","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody, in healthy subjects","volume":"7","author":"Bhattacharya","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.nmd.2020.05.002_bib0047","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/dmcn.12220","article-title":"Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy","volume":"55","author":"Mayhew","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2020.05.002_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160195","article-title":"Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy","volume":"11","author":"Mercuri","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2020.05.002_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221097","article-title":"Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy","volume":"14","author":"Muntoni","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2020.05.002_bib0050","first-page":"149","article-title":"The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials","volume":"87","author":"Ricotti","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"}],"updated-by":[{"DOI":"10.1016\/j.nmd.2021.01.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000}}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620301188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620301188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T10:46:37Z","timestamp":1601030797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896620301188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0960896620301188"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.05.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}